References
- Global Tuberculosis Report 2022. World Health Organization, 2022.
- The End TB Strategy. World Health Organization; 2014. http://www.who.int/tb/strategy/end-tb/en/. Accessed March 14, 2019.
- National Guideline for the Management of Drug-resistant Tuberculosis Cases 2020. Romanian Society of Pneumology 2020. Official Gazette no. 917 bis 2020.10.8
- Paul Ioan Stoicescu et al. Management of Multidrug Resistant Tuberculosis Cases. Ministry of Health, "Marius Nasta" Institute of Pneumology, National Tuberculosis Control Program; 2005
- Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. World Health Organization; 2014
- Arghir OC, Chiotan DI, Cioran NV, et al. Methodological Guideline for the implementation of the National Program for the Prevention, Surveillance and Control of Tuberculosis. Ministry of Health, "Marius Nasta" Institute of Pneumology, National Tuberculosis Control Program; 2015
- Daniela Homorodean, Adriana Moisoiu. National Guideline for the TB Laboratory Network. Ministry of Health, "Marius Nasta" Institute of Pneumology, National Tuberculosis Prevention, Surveillance and Control Program; 2017
- WHO Treatment Guidelines for Isoniazid-Resistant Tuberculosis: Supplement to the WHO Treatment Guidelines for Drug-Resistant Tuberculosis. World Health Organization; 2018
- Ahuja SD, Ashkin D, Avendano M, et al. 'Aultidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Ir/hvidual Patient Data Meta-analysis of 9,153 Patients. PLOS Med. 2012; 9(8):e 1001300
- Fox GJ, Mitnick CD, Benedetti A et al. Surgery as an adjunctive treatment for multidrug-resistant tuberculosis: an individual patient data metaanalysis. Clin Infect Dis. 20l6; 62(7):887-895
- Harris RC, Khan MS, Martin LJ, et al. The effect of surgety on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2016; 16:262
- Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One. 2015 Mar 23;10(3):e0119628. doi: 10.1371/journal.pone.0119628. PMID: 25799046; PMCID: PMC4370653.
- World Health Organization. Global Tuberculosis Report. Geneva, Switzerland; WHO press; 2013.
- World Health Organization; Multidrug and Extensively Drug-Resistant TB 2010 Global Report of Surveillance and Response. Geneva, Switzerland; WHO press; 2010.
- Sougakoff W. Molecular epidemiology of multidrug-resistant strains of Mycobacterium tuberculosis. Clin Microbiol Infect. 2011; 17: 800–805. 10.1111/j.1469-0691.2011.03577.x
- Erdenegerel Narmandakh, Oyuntuya Tumenbayar, Tsetsegtuya Borolzoi, Baasansuren Erkhembayar, Tsolmon Boldoo, Naranzul Dambaa, Buyankhishig Burneebaatar, Naranbat Nymadawa, Satoshi Mitarai, Sarantuya Jav, Chen-Yuan Chiang. Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia. ASM Journals, Antimicrobial Agents and Chemotherapy Vol. 64, No. 7. https://doi.org/10.1128/aac.00537-20
- Jindani A, Aber VR, Edwards EA, Mitchison DA. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121:939–949.
- Zhang Y, Heym B, Allen B, Young D, Cole S. 1992. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591–593.
- Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR, Jr. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227–230.
- Vilchèze C, Jacobs WR. 2014. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr 2:MGM2.
- Lempens P, Meehan CJ, Vandelannoote K, Fissette K, de Rijk P, Van Deun A, Rigouts L, de Jong BC. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci Rep. 2018 Feb 19; 8(1):3246. doi: 10.1038/s41598-018-21378-x. PMID: 29459669; PMCID: PMC5818527.
- Vilcheze C, Jacobs WR., Jr. Resistance to isoniazid and ethionamide in mycobacterium tuberculosis: genes, mutations, and causalities. Microbiology Spectrum. 2014;2:MGM2-0014-2013. doi: 10.1128/microbiolspec.MGM2-0014-2013.
- Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PloS one. 2015;10:e0119628. doi: 10.1371/journal.pone.0119628.
- Böttger, E. C. In Antituberculosis Chemotherapy Vol. 40 (eds P. R. Donald & P. D. van Helden) Ch. 14, 128–144 (Karger, 2011).
- Huyen MN, et al. Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes. Antimicrobial agents and chemotherapy. 2013;57:3620–3627. doi: 10.1128/AAC.00077-13.
- Ramaswamy SV, et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy. 2003;47:1241–1250. doi: 10.1128/AAC.47.4.1241-1250.2003.
- Jagielski T, et al. Identification and analysis of mutations in the katG gene in multidrug-resistant Mycobacterium tuberculosis clinical isolates. Pneumonologia i alergologia polska. 2013;81:298–307.